奥星药业 2024年度报告

Quarterly Report For the period endingMarch 31, 2025(the “Reporting Period”) Outstanding SharesThe number of shares outstanding of our Common Stock was: 381,209,195 as of March 31, 2025(Current Reporting Period Date or More Recent Date)341,209,195 as of June 30, 2024(Most Recent Completed Fiscal Year End) Shell StatusIndicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934): Yes:☐ Indicate by check mark whether the company’s shell status has changed since the previous reporting period: Yes:☐ Change in ControlIndicate by check mark whether a Change in Control4of the company has occurred during this reporting period: Yes:☐ 4“Change in Control” shall mean any events resulting in: (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act),directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding votingsecurities; (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to 1)Name and address(es) of the issuer and its predecessors (if any) In answering this item, provide the current name of the issuer and names used by predecessor entities, along with thedates of the name changes. The current name of the issuer is “Aoxing Pharmaceutical Company, Inc.”The issuer’s name was “China Aoxing Pharmaceutical Co., Inc.” until March 2010.The issuer's name was “Central American Equities Corp.” until July 2006. Current State and Date of Incorporation or Registration: FL, incorporated on 1/23/1996Standing in this jurisdiction: (e.g. active, default, inactive): Active Prior Incorporation Information for the issuer and any predecessors during the past five years: The issuer has been domiciled in FL since incorporation. In September 2019, the entity became inactive with the state ofFL for failure to file required annual reports. On August 11th2023, the Custodian reinstated the entity in FL and appointeda new Registered Agent. The entity remains in active status. Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessorssince inception: N/A List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated orthat occurred within the past 12 months: On September 12th2024, a collective group of buyers entered into a Securities Purchase Agreement for 305,000,000shares of Common Stock representing 80% control of the Company, which was closed subsequent to the period coveredby this report. Address of the issuer’s principal executive office: Flat F, 9/F, Block 25, South Horizons,Apleichau, Hong Kong Address of the issuer’s principal place of business:☒Check if principal executive office and principal place of business are the same address: Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past fiveyears? No:☐Yes:☒If Yes, provide additional details below: On June 28th 2023, the Eleventh Judicial Circuit Court in Miami-Dade County, Florida, entered an Order appointing DavidDuarte as Custodian of Aoxing Pharmaceutical Company, Inc. (case number: 2022-021295-CA-01). Pursuant to theorder, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and it’s shareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholdersmeeting, filing of disclosures with OTC Markets, filing of tax returns, disclosure of capital structure and/or business plan,and to exercise the corporate powers of the Company and its board of directors or officers. On February 2nd 2024, the Eleventh Judicial Circuit Court granted the Custodian’s Motion to Discharge, and on February5th the Order Discharging Custodian and Termination of Custodianship was entered and control of the Company wasreturned to it’s Board of Directors. 2)Security Information Transfer Agent Name:Olde Monmouth Stock Transfer CO., Inc.Phone:(732) 872-2727Email:matt@oldemonmouth.com Publicly Quoted or Traded Securities: The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equitysecurities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that arepublicly traded/quoted. Trading symbol:AOXGExact title and class of securities outstanding:CommonCUSIP:03740A106Par or stated value:0.0001Total shares au